HIGHLIGHTS OF THE CONFERENCE
- Explore the Implications of a Changing Health System on Cancer Prevention and Control.
- Impact of Disparities on Access and Quality of Cancer Prevention and Control.
- Cancer Prevention and Focus on Primary Prevention.
- Identify how Effectively Address Cancer Survivorship Across the Continuum.
- New Innovations in Cancer Research and Technology.
- Global Cancer Initiatives.
- Better Clinical Practice.
INVITATION TO 9TH WORLD CANCER CONGRESS - 2025
Arjyopa Healthcare welcomes you to attend the 9th World Cancer Congress - 2025 during November 20th - 21st, 2025 at JNU Convention Centre, JNU Campus, New Delhi, India. We cordially invite all the participants interested in sharing their knowledge and research in the arena of Oncology and Cancer Research. As a host we feel excited that our past 8th Editions of WCC has able to create impact in people life and which resulted in fruitful collaborations and rewarding experiences for the researchers and speakers. We are also happy that WCC Series has helped them enhance their work practice and impact on their research.
The WCC is a global platform for the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy. The WCC-2025 Conference aims to offer global forum for experts, researchers, and participants to discuss latest research in Cancer and Oncology.
The aim and goal of this year summit is to bridge basic and clinical aspects of the genesis, progression, prognosis, prevention, and treatment of cancer. The summit is focused upon disease management, prevention, strategies for early diagnosis, and specific classes of therapeutic agents, results of a clinical trial, an emerging interventional technique, supportive care, and rehabilitation/reconstruction. The conference will provide an ideal platform for knowledge transfer, B2B networking and collaborations along with a delightful experience of a scientific meeting combined with social evenings which will set a perfect backdrop for The 9th World Cancer Congress-2025.
We look forward to the honor of welcoming you at New Delhi, India during the conference week
ORGANIZING CHAIRMAN MESSAGE
Dear Colleague,
On behalf of the Organizing Committee, I am delighted to INVITE you to attend the “9th World Cancer Congress - 2025”, which will take place in New Delhi-The Capital City of India from 20th – 21st November, 2025.
The summit will be organised around the theme of “Integrative Medicine and Translation Research in Cancer”. It will bring together leading experts from around the world to share the latest advances and best practices in cancer care. The summit will cover a wide range of topics, including cancer screening and prevention, early onset adult cancers, cellular therapies and novel systemic therapies, palliative care and surgical and radiation oncology updates etc.
This event will be an important meeting point to inspire and connect leaders, decision makers, doctors, scientists, technologists, public servants and academics to enhance awareness, quality and safety practices to improve the lives of patients with cancer around the world. The conference will provide the ideal forum to discuss the latest findings and to improve the outcomes for patients with cancer, which is still one of the biggest challenges of the 21st century. I wish you all a productive and successful conference and look forward to seeing the results of your debates, discussions and knowledge sharing put into practice.
We hope to see you during the conference week at the capital city of India.
With Warm Regards
Dr. Kodaganur . S. Gopinath
(Padma Shri Awardee-2010)
Consultant Surgical Oncologist & Director
HCG, India
ORGANIZING & SCIENTIFIC COMMITTEE
Dr. Kodaganur . S. Gopinath
Senior Oncologist & Director,
HCG, INDIA
Dr. Sanjay Sharma
Senior Oncologist & Director,
Asian Cancer Institute, Mumbai
Dr. G. K. Rath
Retd. Head, Dept of Radiation Oncology,
AIIMS, New Delhi
Dr. Arnab Gupta
Senior Oncologist and Director,
Saroj Gupta Cancer Centre & Research Institute, Kolkata
Prof. Dilip Kumar Parida
Professor & Medical Superintendent,
AIIMS, Bhubaneswar
Dr. Birandra K Sinha
Senior Scientist,
NIH, USA
Dr. Ashok Sharma
Asso. Professor, Dept. of Biochemistry,
AIIMS, New Delhi
- Track 1: Oncology
- Track 2: Different Types of Cancer
- Track 3: Cancer Biology
- Track 4: Cancer Treatment and Therapy
- Track 5: Covid and Its Impact on Cancer
- Track 6: Role of AI in Cancer
- Track 7: Cancer Epidemiology
- Track 8: Breast Cancer
- Track 9: Cancer Biomarkers
- Track 10: Imaging
- Track 11: Medical Oncology
- Track 12: Robotic Oncology
- Track 13: Pediatric Oncology
- Track 14: Oncology Nursing
- Track 15: Neuro-Oncology
- Track 16: Cancer Pharmacology
- Track 17: Skin Cancer
- Track 18: Radiation Oncology
- Track 19: Cancer Drug Market
- Track 20: Gynecologic Cancer
- Track 21: Cancer Metastasis
- Track 22: Sarcoma
- Track 23: Head and Neck Cancer
- Track 24: Organ Specfic Cancer
ABSTRACT SUBMISSION
Authors are invited to submit abstract(s) using the submission form on this page. Abstracts should contain sufficient detail on the techniques used and the results, which will be shown. You will receive a confirmation when the abstract has been received. Please contact the conference secretariat if you did not receive confirmation within 5 working days. Submission implies the intent of at least one author to register, attend the symposium and present the paper orally or in poster format. Contributions will only be finally accepted after registration and payment of the conference fee. The abstract will be reviewed, and you will be notified of acceptance.
- The entire body of the abstract, excluding tables, must not exceed 250 words. Spaces are not included in this number. Title, authors’ names, affiliations, figures, and tables are not included in the character count.
- The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.
- Do not use bold type or underline formatting. Italic type is acceptable.
- Text may be in multiple paragraphs.
- Any references should be noted as citations within the text and not as footnotes at the end
Important Dates
1st Phase Abstract Submission will closes: 15th January, 2025
Early Bird Registration Closes: 17th November, 2024